Biotek-snakken — Marts 2020
-
-
-
Begge selskaber jeg gerne vil have fat i, men nu koster de en del og markedsværdien er høj, så afventer lige at de beviser noget i klinikken. Arvinas har vist i klinikken at deres PROTAC er oralt tilgængeligt og nu må vi se om der er et terapeutisk vindue !
-
Hansa Biopharma: https://www.proinvestor.com/index.php?p=debat_1&postid=82339
-
-
https://finance.yahoo.com/quote/IGMS?p=IGMS IGM på tilbud sukkeralf
-
Hansa Biopharma announces long term follow-up data that demonstrates 2-year graft survival of 89% after imlifdase treatment and transplantation.
https://www.proinvestor.com/?p=debat_1&postid=82339&thread=50&start=#82351 -
BIOTEKAKTIER KAN FORGYLDES AF AMERIKANSK BLÅSTEMPLING
Medvind fra de amerikanske lovgivere kan betyde aktieafkast og reducerede risici i biotekaktier, vurderer kapitalfond. I november blev Orphazyme blåstempelet i USA, og siden er selskabets
aktie steget med 94,2 pct.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

